Background
Retrospective multicenter cohort of 645 anti-VEGF–naive metastatic RCC patients treated with sunitinib, sorafenib, or bevacizumab plus interferon (2004–2008). Cox regression with bootstrap validation identified independent prognostic factors for OS, deriving the IMDC (Heng) model still used for risk stratification and trial enrollment.
Interventions and follow up
Design: International consortium prognostic model derivation in first-line VEGF-targeted therapy.
Primary endpoint: Overall survival.
Method: Multivariable Cox regression with internal bootstrap validation.
Primary endpoint: Overall survival.
Method: Multivariable Cox regression with internal bootstrap validation.
Results
Time from dx to tx <1yr: HR 1.45, 95%CI 1.07–1.84, P<.01.
Hemoglobin <LLN: HR 1.74, 95%CI 1.27–2.22, P<.0001.
Neutrophils >ULN: HR 2.46, 95%CI 1.42–3.49, P<.0001.
Platelets >ULN: HR 1.52, 95%CI 0.99–2.06, P<.01.
Corrected calcium >ULN: HR 1.89, 95%CI 1.11–2.68, P=.0006.
Karnofsky PS <80%: HR 2.59, 95%CI 1.86–3.33, P<.0001.
Risk groups (2-yr OS): Favorable (0 factors) mOS not reached, 75%; Intermediate (1–2) mOS 27mo, 53%; Poor (≥3) mOS 8.8mo, 7%; whole cohort mOS 22mo. LDH and prior nephrectomy were not significant.
Hemoglobin <LLN: HR 1.74, 95%CI 1.27–2.22, P<.0001.
Neutrophils >ULN: HR 2.46, 95%CI 1.42–3.49, P<.0001.
Platelets >ULN: HR 1.52, 95%CI 0.99–2.06, P<.01.
Corrected calcium >ULN: HR 1.89, 95%CI 1.11–2.68, P=.0006.
Karnofsky PS <80%: HR 2.59, 95%CI 1.86–3.33, P<.0001.
Risk groups (2-yr OS): Favorable (0 factors) mOS not reached, 75%; Intermediate (1–2) mOS 27mo, 53%; Poor (≥3) mOS 8.8mo, 7%; whole cohort mOS 22mo. LDH and prior nephrectomy were not significant.
Adverse events
Toxicity data: Not a study endpoint; this was a retrospective prognostic registry analysis without prospective adverse-event capture.
Safety relevance: NR — treatment-related toxicities were not systematically reported.
Safety relevance: NR — treatment-related toxicities were not systematically reported.
Conclusions
Six independent factors define the IMDC (Heng) prognostic model, stratifying metastatic RCC into favorable, intermediate, and poor risk groups now standard for therapy selection and clinical-trial stratification.
Key Limitations
Retrospective design with potential selection bias; derived in the VEGF-TKI era and predates immune checkpoint combinations, though the model remains validated and prognostic in the IO era.
Clinical Context
IMDC risk classification underpins ASCO/ESMO treatment algorithms for advanced RCC, guiding choice and intensity of first-line IO-based therapy and serving as the standard stratification factor in modern RCC trials.
References